Applicants,Chemical_Name,Funding_requested_for,Pharmaceutical,Priority_List,Schedules,Therapeutic_group
"ABBVIE LIMITED, Clinician",Upadacitinib,"Crohn's disease, severe, 1st line biologic",Upadacitinib (RINVOQ),Only if cost neutral or cost saving,Community and Hospital,Alimentary Tract and Metabolism
